A pharmaceuticals company will have to cut dramatically the price of an epilepsy drug after losing its legal action against the competition watchdog.
Flynn Pharma had previously been fined £5.2 million by the Competition and Markets Authority after the price of phenytoin sodium capsules that it sold rose by 2,600 per cent.
Pfizer, which manufactured the capsules and struck a deal with Flynn prior to the price rise, was fined a record £84.2 million as part of the same CMA decision.
In a hearing last week, Flynn asked the Competition Appeal Tribunal to suspend the CMA’s ruling that it had to decrease the price of the medicine by today because it plans to file an appeal against the watchdog’s decision.
Full Content: The Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ Antitrust Chief Gail Slater Assembles Veteran Team for Key Cases
Mar 16, 2025 by
CPI
UK Demands Access to Apple’s Encrypted Cloud Data, Spark Legal and Privacy Battle
Mar 16, 2025 by
CPI
Turkey Probes Netflix, Disney+, and Amazon Over Anti-Competitive Practices
Mar 16, 2025 by
CPI
Elon Musk and OpenAI Agree to Accelerate Trial Amidst Legal Battle Over AI’s For-Profit Shift
Mar 16, 2025 by
CPI
AI in Markets: A Double-Edged Sword for Competition, Says CCI Chief
Mar 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li